PD-161570
Product Sizes
10 mg
£ POA
HY-100434-10MG
5 mg
£ POA
HY-100434-5MG
50 mg
£ POA
HY-100434-50MG
25 mg
£ POA
HY-100434-25MG
10mM/1mL
£ POA
HY-100434-10MM
About this Product
- SKU:
- HY-100434
- CAS Number:
- 192705-80-9
- Extra Details:
- PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. PD-161570 also inhibits the PDGFR; EGFR and c-Src tyrosine kinases with IC50 values of 310 nM; 240 nM; and 44 nM; respectively. PD-161570 inhibits PDGF-stimulated autophosphorylation and FGF-1 receptor phosphorylation with IC50s of 450 nM and 622 nM; respectively[1][2]. PD-161570 is also a bone morphogenetic proteins (BMPs) and TGF-β signaling inhibitor[3].
- Molecular Weight:
- 532.51
- Purity:
- 99.82
- References:
- [1]Hamby JM, et al. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J Med Chem. 1997 Jul 18;40(15):2296-303.|[2]Batley BL, et al. Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor. Life Sci. 1998;62(2):143-50.|[3]Wolfe A, et al. Pharmacologic characterization of a kinetic in vitro human co-culture angiogenesis model using clinically relevant compounds. J Biomol Screen. 2013 Dec;18(10):1234-45.|[4]Kyosuke Hino, et al. An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva. Stem Cell Reports. 2018 Nov 13;11(5):1106-1119.
- Research Area:
- Cancer; Cardiovascular Disease
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C; 3 years; 4[o]C; 2 years (Powder)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;TGF-beta/Smad
